Why salt therapy is making a real comeback in modern wellness with renewed interest in its respiratory and skin healing ...

Indeed, the first AhR-activating drug tapinarof (VTAMA®) was recently approved for the treatment of psoriasis and atopic ... resolve inflammation and promote mucosal healing.

Shallow ulceration was seen on the oral mucosa, a finding consistent with ... chronic conditions such as eczema, psoriasis, and seborrheic dermatitis are often severe and untreated.

Importantly, the mucosal gene signature of T FH cells also ... offering an actionable target to treat psoriasis by inhibiting fatty acid synthesis. Single-cell multiomic analysis of Graves ...

Common examples of autoimmune disease include type 1 diabetes, rheumatoid arthritis, multiple sclerosis and psoriasis ... within the small bowel mucosa in celiac disease. In this Perspective ...

Additionally, IL-23 p19 inhibitors were analyzed in clinical trials and observational studies due to their efficacy in various immune-mediated diseases, such as psoriasis and ankylosing ... APS); ...

Psoriasis significantly impacts psychological and social well-being, with high rates of depression, anxiety, and suicidal ideation among patients. Effective management requires a holistic, patient ...

Patients with type 2 diabetes (T2D) who have psoriasis showed an increased risk for renal disease, including diabetic neuropathy, chronic kidney disease (CKD), end-stage renal disease (ESRD), and ...

Patanjali Ayurved's research, published in the Journal of Inflammation Research, reveals promising results for their Ayurvedic treatment of psoriasis using Psorogrit tablets and Divya Taila.

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily pill helped patients achieve clear or almost clear skin.